Dr. Hanna Y. Irie

BCA 2026 Exceptional Project Grantee

Hanna Y. Irie MD, PhD, is an Associate Professor at the Tisch Cancer Institute in the Division of Hematology and Medical Oncology of the Icahn School of Medicine at Mount Sinai in New York City. She is a physician-scientist whose research program is focused on helping more patients achieve lifelong remission from breast cancer by identifying and translating novel therapeutic targets for high-risk breast cancers, especially drug-resistant and metastatic disease. Dr. Irie received her MD and PhD degrees from Harvard Medical School, where she also completed her post-doctoral research fellowship. She completed her clinical fellowship in Medical Oncology at the Dana-Farber Cancer Institute and Massachusetts General Hospital.

While maintaining an active clinical practice as a breast medical oncologist, she has led collaborative, translational efforts at the Dubin Breast Center of Mount Sinai, including the creation of the Breast Tumor Biorepository and generation of patient-derived xenograft (PDX) models of breast cancers from diverse populations. Dr. Irie’s research team has identified novel therapeutic targets for drugresistant breast cancers. With validation using these unique PDX models, the team has partnered with chemical biologists to develop novel, first-in-class therapeutic compounds for clinical translation.

Dr. Irie has published widely in Nature Communications, Cell Reports, Cancer Research, NPJ Breast Cancer, Breast Cancer Research and Oncotarget, and her research has received support from the Breast Cancer Alliance, Department of Defense Breast Cancer Research Program, the American Cancer Society, the Breast Cancer Research Foundation, AACR, ASCO and Susan G. Komen for the Cure.